Skip to content

Rivaroxaban for stroke prevention in atrial fibrillation – Video abstract [30159]

  • by

Video abstract of review paper “Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation” published in the open access journal Therapeutics and Clinical Risk Management by Turpie AGG.

Atrial fibrillation usually shortened to af is the most common cardiac arrhythmia and affects 2% of the developed world’s population this burden is predicted to increase father as a proportion of elderly population arises ef occurs due to the firing of irregular electrical impulses leading to impaired blood flow an individual with ef is five times more at risk of a

Stroke and three times more at risk of developing congestive heart failure and someone without the earth furthermore ef related strokes are often more serious and disabling and nany affiliated straws they’re for stroke prevention and patient with ef is of critical importance in fact of anticoagulation reduces the risk of stroke until recently vitamin k antagonists

Such as warfarin with a therapy of choice but were associated with some limitations such as a need for routine coagulation monitoring increased drug drug interactions and dietary restrictions guidelines in the eu and the u.s. now recommend the use of novel direct oral anticoagulants such as rivaroxaban apixaban the bigger trended dog salon in preference to vitamin

K antagonist for stroke production in patients with ef this review focuses on the direct factor 10 inhibitor rivaroxaban rivaroxaban 20 milligrams once daily is approved in the eu the us and canada for the prevention of stroke and systemic embolism in cases with non-volatile fibrillation and one or more risk factors including congestive heart failure hypertension

Age 75 years or older diabetes mellitus or prior stroke or transient ischemic attack the approval of rivaroxaban in this indication was based on the results of the phase three rocket af trial in which rivaroxaban was found to be not inferior to warfarin for stroke reduction with a similar risk of major and clinically-relevant non-major bleeding and a reduction in

The risk of intracranial hemorrhage and fatal bleeding this review explains what makes river ups about an effective convenient alternative to warfarin for stroke reduction in patient of ef i discussed rivaroxaban is predictable pharmacokinetic and pharmacodynamic profiles the oral once daily dosing regimen practical considerations for its clinical use such as dose

Reductions in high-risk patients including those with renal impairment switching between anticoagulant therapies management of major bleeding and measurement of rivaroxaban exposure i also discusses other approved cardiovascular indications such as venous thromboembolism prevention after elective hip or knee replacement surgery treatment of deep vein thrombosis

Or pulmonary embolism and secondary prevention in acute coronary syndrome although rivaroxaban is only approved in europe for the latter how even established as an effective antique wagon turn phase 3 clinical trials registries such as garfield and orbit ef and the ongoing phase four trials will evaluate the use of lorac seban in the real-world setting across it’s

Approved indications the results of these trials are eagerly awaited and will offer welcome insight into what the future holds for rivaroxaban and the patients who may benefit from it i invite you to read the full article thank you

Transcribed from video
Rivaroxaban for stroke prevention in atrial fibrillation – Video abstract [30159] By Dove Medical Press